Nutriband, Inc. NTRB 深 沪
已收盘 08-01 16:00:00 美东时间
7.39
+0.180
+2.50%
华盛通- 最 高7.67
- 今 开7.28
- 成交量 1.41万股
- 最 低 7.13
- 昨 收 7.21
- 总市值 8225.29万
- 52周最高 11.78
- 市盈率 静 --
- 换手率 0.13%
- 52周最低 3.7223
- 委 比 64.29%
- 总股本 1113.03万
- 历史最高 11.78
- 量 比 0.41
- 振 幅 7.49%
- 历史最低 1.53
- 每 手 1
- 风险率 1.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nutriband To Issue 25% Preferred Stock Dividend To Shareholders Of Record On July 25, Convertible Upon FDA Approval Of AVERSA Fentanyl
Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") is today reminding shareholders of the key dates associated with its upcoming 25% Preferred stock dividend.Shareholders of record on July
07-18 21:37
Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval
Nutriband Inc. is informing shareholders about upcoming key dates for its 25% Preferred stock dividend. Shareholders of record on July 25, 2025, will receive one preferred share for every four common shares held, with the payout on August 5. Each preferred share is convertible to one common share upon FDA approval of the company's AVERSA Fentanyl product, which uses abuse-deterrent transdermal technology. If unconverted, preferred shares will ear...
07-18 13:15
美股牛股 | 金矿股Blue Gold上市累涨12倍！Bakkt、BitMine集体宣布加密货币储备
金矿股Blue Gold上市累涨12倍！计划收购金矿资产；Bakkt、BitMine集体宣布加密货币储备，隔夜股价分别大涨32%、27%>>
07-03 19:32
Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval
Nutriband Inc. announced a 25% preferred stock dividend, with eligible shareholders receiving one preferred share for every four common shares held, based on July 25, 2025 records, payable on August 5. Each preferred share is convertible into one common share upon FDA approval of their AVERSA fentanyl product. If unconverted, preferred shares will receive annual cash dividends. The company focuses on developing abuse-deterrent fentanyl patches us...
07-02 12:05
Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index
Nutriband Inc. has been added to four Russell indexes as part of the 2025 reconstitution, reflecting its growth and market focus. The company's AVERSA technology aims to revolutionize the safety profile of abused medications like fentanyl, with potential peak annual sales of $80 million to $200 million. Russell indexes, managed by FTSE Russell, are widely used by investors and represent $10.6 trillion in assets. Nutriband continues to develop its...
07-01 11:00
Nutriband Completes Commercial Manufacturing Process Scale-Up For Aversa Fentanyl, With Kindeva
Nutriband and Kindeva have completed commercial manufacturing process scale-up for its lead product Aversa™ Fentanyl, an abuse-deterrent fentanyl patchNutriband is partnering with Kindeva to develop Aversa™
06-18 19:01
Nutriband issued U.S. patent for transdermal abuse deterrent technology
Nutriband (NASDAQ:NTRB) has announced that the U. S. Patent and Trademark Office issued patent number 12,318,492 on June 3, 2025, entitled "Abuse and Misuse Deterrent Transdermal Systems." The issuanc...
06-09 20:21
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology
Nutriband Inc. announces the issuance of U.S. Patent No. 12,318,492 for its AVERSA™ abuse-deterrent transdermal technology, expanding its intellectual property protection in the U.S. This technology, which prevents drug abuse, misuse, and diversion, is already patented in 46 countries, including the U.S., Europe, Japan, China, and Australia. Nutriband's lead product, Aversa™ Fentanyl, an abuse-deterrent pain patch, has the potential to generate $...
06-09 11:30
Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference
Nutriband Inc. CEO Gareth Sheridan will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on June 5th at 4PM EST. The event includes a fireside Q&A and 1x1 investor meetings. The live presentation and archived webcast will be available on the company's website and Channelchek. Nutriband focuses on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch using AVERSA™ t...
06-03 12:00
Nutriband Q1 EPS $(0.12) Beats $(0.20) Estimate, Sales $667.43K Miss $705.00K Estimate
Nutriband (NASDAQ:NTRB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.20) by 40 percent. This is a 42.86 percent increase over losses of $(0.21) per share from the same
06-02 20:19
